Solid Malignancies
23
8
9
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.0%
3 terminated out of 23 trials
72.7%
-13.8% vs benchmark
0%
0 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (23)
A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Theranostic PET for Target Validation and Tumor Detection
Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.